drugset / Trial / NCT04802967

A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males

NCT04802967

Phase 1 Completed 141 enrolled Dompé Farmaceutici S.p.A
RandomizedParallel-groupDouble-blindTreatment

Summary

Part A The primary objective of this study is to determine the single dose pharmacokinetics (PK) of ketoprofen lysine salt combined with gabapentin (KLS-GABA \[80 mg-34 mg\]) compared to KLS alone (80 mg) in healthy male subjects. The secondary objective of this study is: • To determine the safety and tolerability of a single oral dose of KLS-GABA (80 mg-34 mg) compared to KLS alone (80 mg) in healthy male subjects. Part B The primary objective of this study is to determine the pharmacodynamic (PD) effects of KLS-GABA in the Intradermal (ID) capsaicin model in healthy male subjects. The secondary objectives of this study are: * To further investigate the safety, tolerability, and PK of single oral doses of KLS-GABA and KLS alone. * To investigate the possible relationship between plasma levels of drug and efficacy in pain reduction.

Timeline

Start
2021-02-08
Primary completion
2022-03-30
Completion
2022-04-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gabapentin Small molecule 17 mg Oral
Comparator Gabapentin Small molecule 34 mg Oral
Comparator Gabapentin Small molecule 68 mg Oral
Comparator Gabapentin Small molecule 300 mg Oral
Comparator Ketoprofen Small molecule 40 mg Oral
Comparator Ketoprofen Small molecule 80 mg Oral
Comparator Ketoprofen Small molecule 160 mg Oral

Indications

No indication recorded.